Cagrilintide — reference
Long-acting amylin analog studied for weight management, primarily as the amylin half of the CagriSema combination.
Regulatory status
Not FDA-Approved. Not FDA-approved as a standalone product. Verify current status directly with the FDA.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~7–8 days (159–195h). Novo Nordisk Phase 2/3 trial data; not FDA-approved as monotherapy.
This figure is tagged Clinical trial in our evidence system. This figure comes from published human trial data rather than an approved label. It is real data, but it has not been through regulatory review, and the compound may not be approved for any use. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Cagrilintide FDA-approved?
What is the half-life of Cagrilintide?
How reliable is that half-life figure?
What cautions are associated with Cagrilintide?
Does Peptide Plug publish dosing for Cagrilintide?
Does Peptide Plug sell Cagrilintide?
Related tools
Free, no account required.